Connection

Daniel Judge to Cardiomyopathies

This is a "connection" page, showing publications Daniel Judge has written about Cardiomyopathies.
Connection Strength

6.932
  1. ATTR Epidemiology, Genetics, and Prognostic Factors. Methodist Debakey Cardiovasc J. 2022; 18(2):17-26.
    View in: PubMed
    Score: 0.739
  2. Wild-Type Transthyretin Cardiac Amyloidosis Is Associated with Increased Antecedent Physical Activity. J Cardiovasc Transl Res. 2022 08; 15(4):689-691.
    View in: PubMed
    Score: 0.732
  3. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 06; 34(3):357-370.
    View in: PubMed
    Score: 0.653
  4. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. Amyloid. 2017 Jun; 24(2):92-95.
    View in: PubMed
    Score: 0.528
  5. Genetic evaluation of familial cardiomyopathy. J Cardiovasc Transl Res. 2008 Jun; 1(2):144-54.
    View in: PubMed
    Score: 0.282
  6. Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2006 Oct 03; 48(7):1416-24.
    View in: PubMed
    Score: 0.252
  7. Reversible cardiomyopathy caused by administration of interferon alpha. Nat Clin Pract Cardiovasc Med. 2005 Jan; 2(1):53-7.
    View in: PubMed
    Score: 0.224
  8. Efficacy and Safety of Angiotensin Receptor Blockers in a Pre-Clinical Model of Arrhythmogenic Cardiomyopathy. Int J Mol Sci. 2022 Nov 11; 23(22).
    View in: PubMed
    Score: 0.193
  9. The response to cardiac resynchronization therapy in LMNA cardiomyopathy. Eur J Heart Fail. 2022 04; 24(4):685-693.
    View in: PubMed
    Score: 0.185
  10. Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation. 2021 11 16; 144(20):1600-1611.
    View in: PubMed
    Score: 0.179
  11. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT. ESC Heart Fail. 2021 10; 8(5):3875-3884.
    View in: PubMed
    Score: 0.178
  12. Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. Circulation. 2021 05 11; 143(19):1852-1862.
    View in: PubMed
    Score: 0.174
  13. Exercise triggers CAPN1-mediated AIF truncation, inducing myocyte cell death in arrhythmogenic cardiomyopathy. Sci Transl Med. 2021 02 17; 13(581).
    View in: PubMed
    Score: 0.172
  14. Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. Am Heart J. 2021 03; 233:122-131.
    View in: PubMed
    Score: 0.170
  15. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021 02; 23(2):277-285.
    View in: PubMed
    Score: 0.168
  16. Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy. Circulation. 2019 10 29; 140(18):1491-1505.
    View in: PubMed
    Score: 0.155
  17. Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. Circ Heart Fail. 2019 03; 12(3):e005371.
    View in: PubMed
    Score: 0.150
  18. Cardiac Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics. 2018 10; 142(Suppl 2):S72-S81.
    View in: PubMed
    Score: 0.145
  19. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13; 379(11):1007-1016.
    View in: PubMed
    Score: 0.144
  20. Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018 09; 20(9):899-909.
    View in: PubMed
    Score: 0.142
  21. Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. J Card Fail. 2018 May; 24(5):281-302.
    View in: PubMed
    Score: 0.140
  22. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. Circulation. 2017 Sep 26; 136(13):e200-e231.
    View in: PubMed
    Score: 0.135
  23. Neonatal Transplantation Confers Maturation of PSC-Derived Cardiomyocytes Conducive to Modeling Cardiomyopathy. Cell Rep. 2017 01 10; 18(2):571-582.
    View in: PubMed
    Score: 0.129
  24. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016 07 12; 68(2):161-72.
    View in: PubMed
    Score: 0.125
  25. Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis. J Cardiovasc Transl Res. 2015 Jun; 8(4):264-8.
    View in: PubMed
    Score: 0.115
  26. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015 May; 8(3):519-26.
    View in: PubMed
    Score: 0.114
  27. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015 Mar; 8(2):117-27.
    View in: PubMed
    Score: 0.114
  28. Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. Ann Neurol. 2014 Oct; 76(4):541-9.
    View in: PubMed
    Score: 0.108
  29. Identification of a new modulator of the intercalated disc in a zebrafish model of arrhythmogenic cardiomyopathy. Sci Transl Med. 2014 Jun 11; 6(240):240ra74.
    View in: PubMed
    Score: 0.108
  30. Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol. 2014 Apr; 7(2):230-6.
    View in: PubMed
    Score: 0.106
  31. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012 Aug; 164(2):222-228.e1.
    View in: PubMed
    Score: 0.095
  32. Use of a coronary sinus lead and biventricular ICD to correct a sensing abnormality in a patient with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol. 2006 Mar; 17(3):317-20.
    View in: PubMed
    Score: 0.061
  33. Extensive cardiac allograft vasculitis and concurrent fat necrosis 6 years after orthotopic heart transplantation. J Heart Lung Transplant. 2007 Nov; 26(11):1212-6.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.